金吾财讯 | 欧洲药品管理局（EMA）旗下人用药品委员会（CHMP）在2026年10月的最新会议上发表积极意见，正式推荐批准礼来公司（LLY）旗下的口服减肥药Foundayo（奥福格列酮/Orforglipron）上市。该药为每日一次的口服疗法，适用于成人体重管理及2型糖尿病的治疗。按照欧盟监管流程，CHMP的积极意见将提交至欧盟委员会（EC）进行最终审批。若顺利获批，Foundayo将正式登陆欧盟27个成员国以及挪威、冰岛和列支敦士登等欧洲市场。业内人士分析指出，此前，竞争对手诺和诺德（NVO）的口服版Wegovy已于今年7月率先获得欧盟批准，占据市场先发优势。礼来Foundayo此番迎头赶上并获得欧洲监管部门的关键支持，预示着两家制药巨头在欧洲口服GLP-1减肥药赛道的竞争将全面升级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.